

# ForPatients

*by Roche*

Neuromyelitis Optica Neuromyelitis optica spectrum disorder (NMOSD)

## **Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)**

**Trial Status**  
Completed

**Trial Runs In**  
15 Countries

**Trial Identifier**  
NCT02073279 SA-309JG,  
2015-005431-41 BN40900

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

### ***Trial Summary:***

The objectives of this study are to evaluate the efficacy, safety, pharmacodynamic, pharmacokinetic and immunogenic profiles of satralizumab in participants with NMO and NMOSD.

**Hoffmann-La Roche**  
Sponsor

**Phase 3**  
Phase

---

**NCT02073279 SA-309JG, 2015-005431-41 BN40900**  
Trial Identifiers

---

### ***Eligibility Criteria:***

**Gender**  
All

**Age**  
>=18 Years & <= 74 Years

**Healthy Volunteers**  
No

---